Your leading voice in digital health news
Twitter X Logo

“Unintended consequences” for prescribing software with move to AIP

10 March 2021
By Kate McDonald

Australia's two leading general practice clinical software vendors are reporting teething problems with the introduction of active ingredient prescribing (AIP), with confusion over the lists of medicines that are excluded from the new rules and those where using both active ingredient and brand name is still recommended.

Pharmacy groups are also reporting problems with prescriptions, including complaints that the intention of the prescriber is sometimes unclear and that listing ingredients alphabetically is leading to confusion about dosage.

New rules requiring that doctors prescribe by active ingredient rather than brand became mandatory on February 1 but Pulse+IT sources say some prescribers were unaware of the changes.

Subscribe to read more

Pulse+IT website access

Keep your finger on the pulse with full access to all articles published on pulseit.news
Instant access
All articles
Cancel anytime

Your leading voice in digital health news

Twitter X

Copyright © 2024 Pulse IT Communications Pty Ltd. No content published on this website can be reproduced by any person for any reason without the prior written permission of the publisher. If your organisation is featured in a Pulse+IT article you can purchase the permission to reproduce the article here.
Website Design by Get Leads AU.

Your leading voice in digital health news 

Keep your finger on the pulse with full access to all articles published on 
pulseit.news
Subscribe from only $39
magnifiercrossmenuchevron-down